Glaxosmithkline announced collaboration with Chroma Therapeutics to develop
macrophage-targeted compounds. Chroma has the potential to receive in excess of $1 billion in total milestone and option payments from GSK. Chroma will receive a significant upfront cash payment and GSK will invest in Chroma's Series D equity financing.
Novo Nordisk announced a global workforce reduction of approximately 9,000 positions to streamline operations and reinvest DKK 8 billion (€1 billion) in growth opportunities for diabetes and obesity treatments.
Carbon black manufacturer Orion Engineered Carbons plans to rationalize production lines in North and South America and EMEA.
Merck to acquire the chromatography business of JSR Life Sciences, a leading provider of CDMO services, preclinical and translational clinical research, and bioprocessing solutions.
Building on the April 2025 announcement, Dow will take actions across its three operating segments to support European profitability, resulting in the closure of sites in Germany and the UK.
